Knockdown of USP18 Increases Alpha 2a Interferon Signaling and Induction of Interferon-Stimulating Genes but Does Not Increase Antiviral Activity in Huh7 CellsMURRAY, E. J; BURDEN, Frances; HORSCROFT, Nigel et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 9, pp 4311-4319, issn 0066-4804, 9 p.Article

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entryWESTBY, Mike; SMITH-BURCHNELL, Caroline; MORI, Julie et al.Journal of virology. 2007, Vol 81, Num 5, pp 2359-2371, issn 0022-538X, 13 p.Article

In Vitro Characterization of the Activity of PF-05095808, a Novel Biological Agent for Hepatitis C Virus TherapyLAVENDER, Helen; BRADY, Kevin; TROKE, Phil et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 3, pp 1364-1375, issn 0066-4804, 12 p.Article

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1CORBAU, Romuald; MORI, Julie; KNÖCHEL, Thorsten et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 10, pp 4451-4463, issn 0066-4804, 13 p.Article

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activityDORR, Patrick; WESTBY, Mike; WEBSTER, Rob et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 11, pp 4721-4732, issn 0066-4804, 12 p.Article